TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03172975

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Na-GST-1/Alhydrogel
Description: Recombinant ˆNecator americanusˆ Glutathione-S Transferase adjuvanted with Alhydrogel

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Na-GST-1/Alhydrogel + CPG 10104
Description: Recombinant ˆNecator americanusˆ Glutathione-S Transferase adjuvanted with Alhydrogel and co-administered with CPG 10104, a synthetic oligodeoxynucleotide

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Na-GST-1/Alhydrogel + GLA-AF
Description: Recombinant ˆNecator americanusˆ Glutathione-S Transferase adjuvanted with Alhydrogel and co-administered with an aqueous formulation of Glucopyranosyl-Lipid A (GLA-AF)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Physiological sterile saline solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole
Description: Treatment with 3 daily oral doses of 400 mg albendazole at end of study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole
Description: Treatment with 3 daily oral doses of 400 mg albendazole at end of study.
Study: NCT04755699

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Stimulation
Description: The study involves the administration of various electrical pulses being delivered to muscles and/or the spinal column with an investigational neurostimulator to evoke various limb movements in order to improve functional movement.
Study: NCT02770872

Intervention type: OTHER
Intervention: Observation of SAA on apoB containing lipoproteins
Description: attempting to elicit the conditions by which SAA shifts from apo-A1 containing lipoproteins to apoB containing lipoproteins

Intervention type: OTHER
Intervention: Observation of SAA on apoB containing lipoproteins
Description: attempting to elicit the conditions by which SAA shifts from apo-A1 containing lipoproteins to apoB containing lipoproteins

Intervention type: OTHER
Intervention: Observation of SAA on apoB containing lipoproteins
Description: attempting to elicit the conditions by which SAA shifts from apo-A1 containing lipoproteins to apoB containing lipoproteins
Study: NCT02678702

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-I
Description: CBT-I

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: Treatment as usual

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Treatment as usual
Study: NCT02423733

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Journal
Description: The Journal is a free internet based program for the self-management of depression (www.depression.org.nz) that was developed in New Zealand and capitalizes on the social marketing appeal of Sir John Kirwan, an ex All Black who has described his experiences of depression to help destigmatize mental illness. . The self-help program is based on the cognitive behavioral techniques of behavioral activation and problem solving which teaches patients the skills of problem solving and delivers an evidence based intervention which is personalized for their individual care.
Study: NCT03704428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1314
Description: Pharmaceutical form: Injection solution. Route of administration: subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1314
Description: Pharmaceutical form: Injection solution. Route of administration: subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1314
Description: Pharmaceutical form: Injection solution. Route of administration: subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1314
Description: Pharmaceutical form: Injection solution. Route of administration: subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1314
Description: Pharmaceutical form: Injection solution. Route of administration: subcutaneous injection.
Study: NCT00644033

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Frovatriptan
Description: 2.5 mg tablet administered once daily for 6 days starting 2 days before the anticipated onset of a MAM headache

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Frovatriptan
Description: 2.5 mg tablet administered twice daily for 6 days, starting 2 days before the anticipated onset of a MAM headache.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo tablet administered for 6 days, starting 2 days before the anticipated onset of a MAM headache.
Study: NCT04184466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Aspart
Description: insulin aspart in doses 0.3 IU/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NovoRapid® Penfill®
Description: insulin aspart in doses 0.3 IU/kg
Study: NCT02773849

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ADSTILADRIN
Study: NCT01547208

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate radiofrequency ablation of ventricular tachycardia
Description: Radiofrequency ablation of ventricular tachycardia is performed immediately after an appropriate ICD shock

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation of ventricular tachycardia
Description: Radiofrequency ablation of ventricular tachycardia will be performed after an arrhythmic storm occurs
Study: NCT05155540

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Trevo and or Merci devices for stent retreival
Description: FDA approved devices for stent retrieval during mechanical thrombectomy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Trevo and or Merci devices for stent retreival
Description: FDA approved devices for stent retrieval during mechanical thrombectomy
Study: NCT03172975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole
Description: Treatment with 3 daily oral doses of 400 mg albendazole at end of study.
Study: NCT00697203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalcetrapib
Description: 900mg po daily for 12 weeks
Study: NCT03893422

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WB-010
Description: Medical food formulation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WB-011
Description: WB-011 medical food product

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Capsules identical to those containing WB-010 and WB-011.
Study: NCT03863990

Intervention type: DRUG
Intervention: PAH medication
Description: Any PAH-targeted medication
Study: NCT00255047

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DAPTACEL®. (DTaP), IPOL®., and ActHIB®.
Description: 0.5 mL, Intramuscular
Study: NCT05155540

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Penumbra system for stent aspiration
Description: FDA approved devices for stent aspiration during mechanical thrombectomy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Penumbra system for stent aspiration
Description: FDA approved devices for stent aspiration during mechanical thrombectomy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recombinant tissue plasminogen activator
Description: FDA approved drug for treatment of acute ischemic stroke within 4.5 hours of strokeonset
Study: NCT03705156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZL-2306(nirapairb)
Description: The starting dose is 300 mg or 200 mg based on patient's body weight.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: The starting dose is the matched dose of placebo (3 capsules or 2 capsules).
Study: NCT00255047

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pentacel®: DTaP-IPV/Hib combined
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP-IPV and ActHIB®
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pentacel®: DTaP-IPV/Hib combined
Description: 0.5 mL, Intramuscular
Study: NCT03092531

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive STEPS
Description: Step 1: 2 way SMS text messages; Step 2: Five in-person, counseling sessions. Each counseling session will last approximately 50 minutes.
Study: NCT01163487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dichloroacetate
Description: 25-50mg/kg per day; oral

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EF5
Description: 21 mg/kg; IV
Study: NCT02103504

Intervention type: DEVICE
Group type: OTHER
Intervention: DePuy Attune posterior stabilized fixed bearing total knee replacement
Study: NCT02290223

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Based Treatment Model
Description: Behavioral based treatment consists of four 90 minute group sessions, one meeting per week. The sessions addressed: empowering patients to take an active role in pain management and overall health; pain management lifestyle practices; use of health information technology resources for active self-care; education on neurobiology of pain and opioids; and improving communication with providers.
Study: NCT04326348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQ05105
Description: TQ05105 is a JAK2 inhibitor.
Study: NCT03064191

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: calcium hydroxide chlorhexidine combination
Description: Endodontic intra-canal medicament used for decreasing postoperative signs ans symptoms

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: calcium hydroxide intra-canal medicament
Description: Endodontic intra-canal medicament used for decreasing postoperative signs and symptoms.
Study: NCT03350633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab Injection
Description: Tocilizumab Injection will be intravenously administered with a dose of 8 mg/kg every 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azathioprine
Description: Azathioprine will be orally given at a dose of 2-3 mg/kg/d
Study: NCT01981291

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraneural Injection for Subgluteal Sciatic Nerve Block
Description: The injection will start as the needle penetrates the outermost discernible layer of the nerve (epineurium) under ultrasound guidance. The injection will be adjudicated as intraneural if nerve cross section expansion and a reduction in echogenicity are observed.~Short-axis real-time ultrasound imaging will be used, with an in-plane needle approach.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Perineural Injection for Subgluteal Sciatic Nerve Block
Description: The injection will start as the needle indents the outermost discernible layer of the nerve (epineurium) under ultrasound guidance. The injection will be adjudicated as intraneural if the drug infiltrates the space between the epimysium of the surrounding muscles and the outer epineurium of the sciatic nerve.~Short-axis real-time ultrasound imaging will be used, with an in-plane needle approach.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Femoral Nerve Block
Description: Patients will receive an ultrasound-guided femoral nerve block using a short- or long-acting local anesthetic, as deemed indicated.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral Nerve Block
Description: Patients will receive an ultrasound-guided femoral nerve block using a short- or long-acting local anesthetic, as deemed indicated.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Patient-controlled postoperative analgesia
Description: Patients will receive a patient-controlled intravenous or perineural catheter-based analgesia, depending on their preference and the anesthesiologist's indication.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Patient-controlled postoperative analgesia
Description: Patients will receive a patient-controlled intravenous or perineural catheter-based analgesia, depending on their preference and the anesthesiologist's indication.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepivacaine
Description: Thirty milliliters of 1.5% (wt/vol) mepivacaine will be used for the sciatic nerve block.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mepivacaine
Description: Thirty milliliters of 1.5% (wt/vol) mepivacaine will be used for the sciatic nerve block.
Study: NCT01333059

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Study: NCT02117973

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: iAssist Technique using Persona system vs. the conventional technique using Persona system

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: iAssist Technique using Persona system vs. the conventional technique using Persona system
Study: NCT01333059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Study: NCT02697175

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Live Video-Colposcopy
Description: The colposcopy will be shown in real time on a flat screen

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Live Video-Colposcopy
Description: The TV will be shut off during colposcopy
Study: NCT03109574

Intervention type: DEVICE
Group type: OTHER
Intervention: BioFlo DuraMax Chronic Hemodialysis Catheter

Intervention type: DEVICE
Group type: OTHER
Intervention: Standard of Care Catheter
Study: NCT03121547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol 50 mg Oral Tablet
Description: 1 tablet administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol Hydrochloride 100 mg Extended Release Oral Tablet
Description: 1 tablet administered

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: calcium tablet
Study: NCT01166763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitamin D3
Description: oral capsules, 10,000 IU per week for 6 months
Study: NCT02733367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infacort®
Description: Infacort® is a dry granule formulation of hydrocortisone stored in capsules available in different strengths (0.5, 1.0, 2.0 and 5.0 mg).
Study: NCT01528254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of vildagliptin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vildagliptin
Description: One tablet (50 mg oral) of vildagliptin in the morning and one tablet in the evening with or without food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Twice daily (bid) regimen during or after meals at the same time as vildagliptin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Twice daily (bid) regimen during or after meals at the same time as vildagliptin.
Study: NCT03349749

Intervention type: DEVICE
Intervention: LiDCOplus haemodynamic monitor
Description: Patients in study group receive intravenous fluid bolus as part of standard fluid resuscitation. Fluid responsiveness (i.e. improvement in cardiac output) is estimated using both standard clinical parameters and by LiDCOplus haemodynamic monitor (with the clinician initially blinded to the latter) before a final decision about fluid responsiveness is made.
Study: NCT03376061

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: Tranexamic Acid is a medication used to treat or prevent excessive blood loss from major trauma, post partum, surgery, tooth removal, nose bleeds, and heavy menstruation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: Tranexamic Acid is a medication used to treat or prevent excessive blood loss from major trauma, post partum, surgery, tooth removal, nose bleeds, and heavy menstruation.
Study: NCT02308709

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Ventilation image-guided radiotherapy
Description: Patient's treatment plan will be created and optimized to minimize the dose to highly-functional lung regions
Study: NCT03669185

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pentalong
Description: Pentalong, 2 x daily 1 tablet, intake max. 133 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebos, 2 x daily 1 tablet, intake max. 133 days
Study: NCT03172975

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Albendazole
Description: Treatment with 3 daily oral doses of 400 mg albendazole at end of study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Necator americanus Larval Inoculum
Description: 50 infectious Necator americanus larvae applied via dermal application (challenge infection).
Study: NCT03852537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Methylprednisolone will be administered based on CRP-guided protocol outlined under 'Biomarker-adjusted steroid dosing'.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care as determined by the patients treatment team.
Study: NCT00422500

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Surveys about symptoms, mood, and quality of life.

Intervention type: BEHAVIORAL
Intervention: Telephone Interactive System
Description: Automated telephone system call once a week during therapy, rating of severity of symptoms and daily life interference done with numeric key pad. Post therapy is complete, a call every two weeks for up to six months.
Study: NCT00356434

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Kendall A-V foot impulse pump, model 6060
Description: Will wear device for DVT prevention and receive questionnaire about compliance and comfort. Will also undergo random checks to confirm compliance with instructions and use

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Kendall sequential compression device, model 9525
Description: Will wear device for DVT prevention and receive questionnaire about compliance and comfort. Will also undergo random checks to confirm compliance with instructions and use
Study: NCT01568983

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 500 ml/day Per 100g 6.25 g sucrose 6.25 g maltodextrin 1.3 g citric acid E330 (pH 3.0) 2.5 g Carmine solution E120 (4% carmine colouring agent) 0.025 g blueberry aroma Potassium sorbate E202 water

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Mana-juice
Description: 500 ml/day of a grape,cherry, bilberry,aronia juice 13g carbohydrates/100g 150mg K/100g

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Optijuice
Description: 500 ml/day of a Grape,cherry, bilberry,aronia, black current juice 13g carbohydrates/100g 150mg K/100g
Study: NCT00422500

Intervention type: OTHER
Intervention: Blood Samples
Description: For participating patients, 3 additional tablespoons of blood drawn at the beginning of each chemotherapy treatment (before treatment starts) and at the beginning of each cycle of treatment.
Study: NCT03172975

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Necator americanus Larval Inoculum
Description: 50 infectious Necator americanus larvae applied via dermal application (challenge infection).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Necator americanus Larval Inoculum
Description: 50 infectious Necator americanus larvae applied via dermal application (challenge infection).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Necator americanus Larval Inoculum
Description: 50 infectious Necator americanus larvae applied via dermal application (challenge infection).
Study: NCT03116191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SK-1404
Description: 4 weeks of repeated administration of SK-1404 to the patients of nocturia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SK-1404
Description: 4 weeks of repeated administration of SK-1404 to the patients of nocturia
Study: NCT05466591

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pre-hospital rule-out strategy
Description: Point-of-care troponin measurement for pre-hospital rule-out of acute coronary syndrome
Study: NCT03870646

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Hypertonic saline of NaCl (7%) in combination with hyaluronic acid
Description: Critical adult tracheostomized patients will receive, in the intervention arm, nebulized Hypertonic saline of NaCl (7%) in combination with hyaluronic acid 5ml twice daily for 10 days from the day of the tracheotomy or until decannulation or discharge from the ICU if it happens before. The treatment will be applied through a jet nebulizer located in the inspiratory branch in patients under mechanical ventilation and in the sole tubulant of patients under T-piece oxygen regimen. Salbutamol 100 micrograms / dose, suspension for inhalation in pressure pack: 2 inhalations through the tracheostomy cannula 10 minutes before the application of the nebulization with hypersaline in order to avoid bronchospasm.

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic saline of NaCl (0,9%)
Description: Critical adult tracheostomized patients will receive, in the control arm, nebulized isotonic saline of NaCl (0,9%) 5ml twice daily for 10 days from the day of the tracheotomy or until decannulation or discharge from the ICU if it happens before. The treatment will be applied through a jet nebulizer located in the inspiratory branch in patients under mechanical ventilation and in the sole tubulant of patients under T-piece oxygen regimen. Salbutamol 100 micrograms / dose, suspension for inhalation in pressure pack: 2 inhalations through the tracheostomy cannula 10 minutes before the application of the nebulization with isotonic saline in order to avoid bronchospasm.
Study: NCT04501419

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: US-guided breast biopsy
Description: During this study, women with undergo an US-guided breast biopsy by a radiologist instead of what is typically performed in Nigerian hospitals, which is either a blind biopsy or surgical excision. US-guided breast biopsy is the standard of care in the United States of America because the accuracy is better than blind biopsy and equal to surgical excision.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided breast biopsy training program
Description: This program, developed by experts in Nigeria and the United States of America, certifies that they have the skills required to safely perform these biopsies on patients